Opinion|Videos|July 23, 2024
Private Label Biosimilars
The expert panel discusses the greater potential for private label biosimilars.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Ebola Cases Top 1700 as Unpaid Health Workers Strike
2
Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers
3
FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6
4
Gene Therapy Could Ease Wet AMD's Injection Burden: Carl Regillo, MD
5